CMEvsVisa

CME and V stock compared: price, dividend, valuation and results, from SEC filings.

CME (CME) has a market value of $115B and Visa (V) $708B. Over the last year, with dividends, CME moved +16.4% and V +30.2%. The P/E is 26.0 for CME and 30.1 for V. Dividend yield: CME 1.61%, V 0.65%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CME$115B

    V$708B

    V is 6.2 times CME

  • Revenue, 12 months

    CME$7.0B

    V$45.9B

    V is 6.6 times CME

  • Net income, 12 months

    CME$4.4B

    V$23.5B

    V is 5.3 times CME

  • Operating margin

    CME65.7%

    V61.2%

    4.5 points apart

  • ROIC

    CME12.8%

    V39.2%

    26.4 points apart

  • P/E

    CME26.0

    V30.1

    V is 1.2 times CME

  • Dividend yield

    CME1.6%

    V0.7%

    0.9 points apart

  • 5-year return

    CME+73.8%

    V+108.7%

    34.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CME+73.8%

V+108.7%

10015020020222023202420252026
Returns by period
PeriodCMEWith dividendsVWith dividends
1 year since November 14, 2025+16.4%Price +12.0%+30.2%Price +29.2%
3 years since November 16, 2023+71.1%+19.6% a yearPrice +50.5%+75.5%+20.6% a yearPrice +71.6%
5 years since November 15, 2021+73.8%+11.7% a yearPrice +40.9%+108.7%+15.8% a yearPrice +100.9%
10 years since November 16, 2016+307.8%+15.1% a yearPrice +177.5%+471.3%+19.0% a yearPrice +432.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CMECMEVVisa

Valuation

CMEV
Valuation
Price$319.37$426.46
Market value$115B$708B
Enterprise value (EV)–$716B
P/E26.030.1
P/E, 5-year median24.0–
P/B4.319.9
EV/EBIT–25.5
Free cash flow yield3.8%3.1%

Results and growth

CMEV
Results and growth
Revenue, 12 months$7.0B$45.9B
Net income, 12 months$4.4B$23.5B
Free cash flow, 12 months$4.3B$22.1B
Earnings per share, 12 months$12.19$14.16
Revenue growth, year on year6.4%14.8%
Revenue growth a year, past+5.9%over 5 years+13.8%over 5 years
EPS growth a year, past+13.7%over 5 years–

Margins and returns on capital

CMEV
Margins and returns on capital
Gross margin––
Operating margin65.7%61.2%
Net margin63.7%51.2%
ROIC12.8%39.2%
ROE16.3%64.0%

Balance sheet

CMEV
Balance sheet
Cash$158B$13.8B
Total debt$3.9B$23.0B
Net debt / EBITDA-32.90.3
Interest cover26.3×37.1×

Dividends and buybacks

CMEV
Dividends and buybacks
Dividend yield1.6%0.7%
Dividend per share, 12 months$5.15$2.79
Dividend growth a year, past––
Buyback yield–2.9%
Shareholder yield1.6%3.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CME or V

Didn't find what you were looking for?

Ask us
Which is bigger, CME or Visa?

By market value, Visa ($708B) is about 6.2 times CME ($115B), at today's prices.

How did CME and V stock do over the last 10 years?

Since November 16, 2016, CME's price moved +177.5% and V's +432.5%. With dividends: CME +307.8% (+15.1% a year), V +471.3% (+19.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, CME or V?

The dividend yield at today's price is 1.61% for CME and 0.65% for Visa. Over the last twelve months they paid $5.15 and $2.79 per share.

What is the P/E of CME and V?

At today's price, the P/E is 26.0 for CME and 30.1 for V. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, CME or Visa?

Over the last twelve months, the net margin was 63.7% for CME and 51.2% for Visa, and the operating margin 65.7% and 61.2%. Revenue was $7.0B and $45.9B.

Which is the better investment, CME or Visa?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.